{"id":30564,"date":"2025-03-26T15:32:59","date_gmt":"2025-03-26T07:32:59","guid":{"rendered":"https:\/\/flcube.com\/?p=30564"},"modified":"2025-03-26T15:33:01","modified_gmt":"2025-03-26T07:33:01","slug":"fosun-pharmas-2024-revenue-reaches-rmb-41-1-billion-amid-rd-investment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30564","title":{"rendered":"Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment"},"content":{"rendered":"\n

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196<\/a>, HKG: 2196<\/a>) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a 16.08% YOY increase. The company invested a total of RMB 5.55 billion (USD 764 million) in research and development (R&D), with RMB 4.91 billion (USD 676 million) allocated to the pharmaceutical business.<\/p>\n\n\n\n

Business Sector Performance<\/strong>
The pharmaceutical business generated RMB 28.9 billion (USD 4 billion) in sales, accounting for 70.43% of total revenues. Despite a 4.29% YOY decline, Fosun Pharma’s integration and optimization of R&D systems and focus on advantageous pipelines allowed profits to grow by 65.73% to RMB 3.25 billion (USD 447 million). Sales of core products in anti-tumor and immune regulation, as well as cardiovascular system therapies, saw significant increases of 5.84% and 14.00% to RMB 8.1 billion (USD 1.1 billion) and RMB 1.9 billion (USD 263 million), respectively. Key products including Hanquyou (trastuzumab biosimilar), Hanlikang (rituximab biosimilar), PD-1 inhibitor HanSiZhuang (serplulimab), and heparin series preparations collectively generated sales exceeding RMB 1 billion (USD 138 million) in 2024.<\/p>\n\n\n\n

R&D and Regulatory Milestones<\/strong>
During the period, Fosun Pharma obtained 16 indication approvals for seven novel drugs\/biosimilars, either developed in-house or licensed-in. Eight novel drugs\/biosimilars entered pre-market regulatory review or pivotal clinical stages, with a total of 18 novel drugs\/biosimilars cleared for clinical trials.<\/p>\n\n\n\n

Medical Device and Diagnostic Business<\/strong>
The medical device and diagnostic business recorded RMB 4.3 billion (USD 595 million) in sales, accounting for 10.53% of total revenue. The decline was attributed to reduced COVID-19 product demand, volume-based procurement of diagnostic reagents, and pricing pressures in the diagnostic business.<\/p>\n\n\n\n

Medical and Health Services<\/strong>
Sales of medical and health services grew by 14.61% YOY to RMB 7.6 billion (USD 1.1 billion), increasing the proportion of total revenue from 16.12% to 18.62%. This growth was driven by the construction of key specialties, smart healthcare initiatives, and improvements in integrated operational efficiency.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024…<\/p>\n","protected":false},"author":1,"featured_media":30565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,159,893,892],"class_list":["post-30564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"\nFosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a 16.08% YOY increase. The company invested a total of RMB 5.55 billion (USD 764 million) in research and development (R&D), with RMB 4.91 billion (USD 676 million) allocated to the pharmaceutical business.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30564\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment\" \/>\n<meta property=\"og:description\" content=\"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a 16.08% YOY increase. The company invested a total of RMB 5.55 billion (USD 764 million) in research and development (R&D), with RMB 4.91 billion (USD 676 million) allocated to the pharmaceutical business.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30564\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T07:32:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-26T07:33:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2613-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment\",\"datePublished\":\"2025-03-26T07:32:59+00:00\",\"dateModified\":\"2025-03-26T07:33:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564\"},\"wordCount\":328,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2613-png.webp\",\"keywords\":[\"Finanical Reports\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30564#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30564\",\"name\":\"Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2613-png.webp\",\"datePublished\":\"2025-03-26T07:32:59+00:00\",\"dateModified\":\"2025-03-26T07:33:01+00:00\",\"description\":\"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a 16.08% YOY increase. The company invested a total of RMB 5.55 billion (USD 764 million) in research and development (R&D), with RMB 4.91 billion (USD 676 million) allocated to the pharmaceutical business.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30564\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2613-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2613-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30564#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment - Insight, China's Pharmaceutical Industry","description":"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a 16.08% YOY increase. The company invested a total of RMB 5.55 billion (USD 764 million) in research and development (R&D), with RMB 4.91 billion (USD 676 million) allocated to the pharmaceutical business.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30564","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment","og_description":"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a 16.08% YOY increase. The company invested a total of RMB 5.55 billion (USD 764 million) in research and development (R&D), with RMB 4.91 billion (USD 676 million) allocated to the pharmaceutical business.","og_url":"https:\/\/flcube.com\/?p=30564","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-26T07:32:59+00:00","article_modified_time":"2025-03-26T07:33:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2613-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30564#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30564"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment","datePublished":"2025-03-26T07:32:59+00:00","dateModified":"2025-03-26T07:33:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30564"},"wordCount":328,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30564#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2613-png.webp","keywords":["Finanical Reports","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30564#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30564","url":"https:\/\/flcube.com\/?p=30564","name":"Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30564#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30564#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2613-png.webp","datePublished":"2025-03-26T07:32:59+00:00","dateModified":"2025-03-26T07:33:01+00:00","description":"China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a 16.08% YOY increase. The company invested a total of RMB 5.55 billion (USD 764 million) in research and development (R&D), with RMB 4.91 billion (USD 676 million) allocated to the pharmaceutical business.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30564#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30564"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30564#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2613-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2613-png.webp","width":1080,"height":608,"caption":"Fosun Pharma's 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30564#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2613-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30564"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30564\/revisions"}],"predecessor-version":[{"id":30566,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30564\/revisions\/30566"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30565"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}